Objective: The aim of the study was to analyze the value of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) coated biphasic calcium phosphate (BCP) for the obliteration of middle ear bone defect after mastoid surgery. Methods: Twenty-four specific pathogen-free Sprague-Dawley rats were randomly assigned to the BCP group ( n= 12) and BCP-ErhBMP-2 group ( n= 12; in which BCP scaffold of the granular type was coated with ErhBMP-2). In both groups, BCP scaffold was used to surgically fill the middle ear bulla. New bone formation was evaluated by measuring bone density (%) after 4 and 8 weeks in all rats in both groups. Results: At 4 weeks, new bone was visible at the periphery and center of the middle ear cavity in both groups. In the BCP group, a moderate amount of fibrous tissue had infiltrated into the interspace of the scaffolds. New bone almost totally filled the interspace in the BCP-ErhBMP-2 group. At 8 weeks, copious new bone formation had occurred. Histometric measurements showed that bone density in the BCP group was smaller than in the BCP-ErhBMP-2 group at 4 weeks (25.10% and 38.43%, respectively; p<. 0.05) and 8 weeks (25.54% and 34.18%, respectively; p<. 0.05). Conclusions: New bone formation was greater in the presence of BCP-ErhBMP-2 scaffolds. ErhBMP-2 coated BCP scaffolds is a potentially useful material for middle ear obliteration after mastoidectomy.
|Number of pages||4|
|Journal||International Journal of Pediatric Otorhinolaryngology|
|Publication status||Published - 2013 Sept|
Bibliographical noteFunding Information:
This study was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea ( HI11C0388 ).
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NSSC) (No. 2012M2A2A6035679).
- Bone morphogenetic protein
- Mastoid obliteration
- Otitis media
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health